Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 17, 2024

BUY
$26.88 - $83.49 $14.9 Million - $46.3 Million
554,658 New
554,658 $46.3 Million
Q2 2023

Jul 25, 2023

BUY
$32.62 - $40.75 $2.18 Million - $2.72 Million
66,709 Added 192.7%
101,327 $3.31 Million
Q1 2023

Apr 18, 2023

BUY
$33.36 - $45.71 $1.15 Million - $1.58 Million
34,618 New
34,618 $1.22 Million
Q2 2022

Jul 27, 2022

SELL
$33.93 - $48.92 $30.6 Million - $44.1 Million
-900,678 Reduced 60.45%
589,274 $23.2 Million
Q1 2022

Apr 25, 2022

BUY
$29.74 - $46.0 $43 Million - $66.5 Million
1,445,969 Added 3287.56%
1,489,952 $54.8 Million
Q4 2021

Feb 01, 2022

SELL
$34.35 - $46.38 $1.41 Million - $1.91 Million
-41,134 Reduced 48.33%
43,983 $2.01 Million
Q3 2021

Oct 19, 2021

SELL
$18.54 - $35.74 $2.1 Million - $4.06 Million
-113,516 Reduced 57.15%
85,117 $3.04 Million
Q2 2021

Jul 15, 2021

SELL
$19.79 - $26.99 $641,176 - $874,449
-32,399 Reduced 14.02%
198,633 $3.93 Million
Q1 2021

Apr 26, 2021

BUY
$18.57 - $25.68 $4.29 Million - $5.93 Million
231,032 New
231,032 $5.37 Million
Q4 2020

Feb 01, 2021

SELL
$15.26 - $28.61 $2.1 Million - $3.93 Million
-137,453 Closed
0 $0
Q3 2020

Oct 07, 2020

BUY
$20.58 - $28.96 $2.83 Million - $3.98 Million
137,453 New
137,453 $2.98 Million
Q2 2020

Jul 21, 2020

SELL
$11.15 - $24.64 $1.35 Million - $2.99 Million
-121,510 Closed
0 $0
Q1 2020

Apr 17, 2020

BUY
$8.75 - $16.3 $1.06 Million - $1.98 Million
121,510 New
121,510 $1.43 Million
Q4 2019

Jan 17, 2020

SELL
$7.95 - $11.84 $481,634 - $717,302
-60,583 Closed
0 $0
Q3 2019

Oct 16, 2019

BUY
$10.82 - $14.25 $655,508 - $863,307
60,583 New
60,583 $689,000

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.62B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.